Nacubactam is under clinical development by Meiji Seika Pharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Nacubactam’s likelihood of approval (LoA) and phase transition for Complicated Intra-Abdominal Infections took place on 01 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 01 Jul 2022 increased Nacubactam’s Phase Transition Success Rate (PTSR) for Hospital Acquired Pneumonia (HAP), increased PTSR for Pseudomonas aeruginosa Infections, increased LoA and PTSR for Urinary Tract Infections, and increased PTSR for Ventilator Associated Pneumonia (VAP).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Nacubactam Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Nacubactam overview

Nacubactam (RG6080, RO7079901) is under development for the treatment of complicated urinary tract infections including pyelonephritis and gram-negative bacterial infections such as Pseudomonas aeruginosa infections,hospital acquired bacterial pneumonia, ventilator associated bacterial pneumonia and complicated intra-abdominal infections. The drug candidate is administered intravenously. It is a new molecular entity (NME) and a diazabicyclooctane beta-lactamase inhibitor.

Meiji Seika Pharma overview

Meiji Seika Pharma, a subsidiary of Meiji Holdings Co Ltd, is a pharmaceutical solutions provider. The company is engaged in providing pharmaceutical, veterinary drugs and chemicals used for agriculture. The company offers Streptomycin Meiji, Kanamycin Meiji, Habekacin, Orapenem, Reflex, Sycrest, Depromel and others. It operates manufacturing and development technologies, which provides a series of excellent antibacterial drugs. Meiji Seika Pharma also carries out research and development programs on infectious diseases and central nervous system disorders. The company offers products for human and veterinary care. It operates research centre, laboratories, and agricultural and veterinary research laboratories in Japan. Meiji Seika Pharma is headquartered in Tokyo, Japan.

Quick View Nacubactam LOA Data

Report Segments
  • Innovator
Drug Name
  • Nacubactam
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.